NCT00034762View on ClinicalTrials.gov

Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

473

Participants

Timeline

Start Date

December 31, 2000

Study Completion Date

January 31, 2003

Conditions

DementiaAlzheimer DiseaseMental Disorders

Interventions

DRUG

risperidone

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00034762 - Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease | Biotech Hunter | Biotech Hunter